At the intersection of endomyocardial biopsy and dd-cfDNA, where do we go?
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Cardiac allograft rejection has traditionally been assessed by endomyocardial biopsy (EMB). Blood-based assays such as donor-derived cell-free DNA (dd-cfDNA) are increasingly used, yet emerging data highlight discordance between these approaches. This review evaluates recent data, examines causes of disagreement, and suggests strategies to better align EMB and dd-cfDNA.
Fields of Study & Subjects
Transplantation: Methods and Outcomes
Renal Transplantation Outcomes and Treatments
Organ and Tissue Transplantation Research
Publication details
- Journal / source
- Cardiovascular Pathology
- Volume
- 83
- Pages
- 107825–107825
- Publication date
- 28 March 2026
- Language
- EN